Kanghui Shares 2025 Annual Performance Forecast
Securities code: 603139 Securities abbreviation: Kanghui Shares Announcement number: 2026-005
Shaanxi Kanghui Pharmaceutical Co., Ltd.
2025 Annual Results Forecast
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
According to preliminary calculations by the financial department, Shaanxi Kanghui Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") is expected to suffer a loss in its annual performance in 2025, with a net profit attributable to the owners of the parent company of approximately -327 million yuan.
During the reporting period, the company's non-recurring gains and losses affected an amount of approximately -119 million yuan. It is expected that the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses will be approximately -208 million yuan in 2025.
1. Performance forecast for this period
(1) Performance forecast period
January 1, 2025 to December 31, 2025.
(2) Performance forecast
According to preliminary calculations by the financial department, it is expected that the net profit attributable to the owners of the parent company will be in loss in 2025, and the net profit attributable to the owners of the parent company will be approximately -327 million yuan.
The net profit attributable to the owners of the parent company, excluding non-recurring gains and losses, is expected to be approximately -208 million yuan in 2025.
(3) This performance forecast is the company’s preliminary forecast based on its operating conditions and has not been audited by an accounting firm.
2. Operating results and financial status for the same period last year
(1) Total profit: -121.5404 million yuan. Net profit attributable to owners of parent company:
-89.6255 million yuan. Net profit attributable to owners of the parent company after deducting non-recurring gains and losses: -67.0224 million yuan.
(2) Earnings per share: -0.90 yuan.
3. The main reasons for the expected loss in this period’s performance
During the reporting period, the company's controlled subsidiary Shaanxi Youbang Biomedical Technology Co., Ltd. (hereinafter referred to as "Shaanxi Youbang") stopped production and submitted a pre-reorganization application to the court. In accordance with the "Accounting Standards for Business Enterprises" and accounting policies, and based on the principle of prudence, the company made individual provision for bad debts based on the individual recognition method for the loans receivable from Shaanxi Youbang. This bad debt affected the company's current performance by approximately 125 million yuan.
In view of the fact that Shaanxi Youbang has ceased production and has submitted a pre-reorganization application to the court, it hired an asset appraisal agency to evaluate the value of Shaanxi Youbang's assets. According to the evaluation results, Shaanxi Youbang made an impairment provision for the assets, affecting the net profit attributable to the parent company of approximately 87 million yuan. In addition, Shaanxi Youbang's operating losses totaled approximately 114 million yuan in impact on the company's current performance.
During the reporting period, due to the impact of policy adjustments in the pharmaceutical industry and changes in the macroeconomic environment, the parent company's sales revenue declined slightly. To this end, the company adjusted its sales strategy in a targeted manner and increased investment in channel construction, brand building, etc. At the same time, due to the product transfer stage, the new production base operated simultaneously with the three old production bases, and the overall operating cost accounted for a high proportion. The above factors together led to the parent company's performance losses for the current period.
4. Risk warning
This performance forecast is a preliminary calculation based on the company's financial department's own professional judgment and has not yet been audited by a certified public accountant. The company has no major uncertainties that affect the accuracy of this performance forecast.
5. Other explanations
The above performance forecast data are only preliminary accounting data. The specific and accurate financial data shall be based on the company's officially disclosed audited 2025 annual report. Investors are advised to pay attention to investment risks.
Announcement is hereby made.
Shaanxi Kanghui Pharmaceutical Co., Ltd. Board of Directors
January 24, 2026